---------------------------------------------------------------
  详细处方信息以本药内容附件PDF文件（20126700480021.PDF）的“原文Priscribing Information”为准
---------------------------------------------------------------

商品名：ヴィーン３Ｇ注

薬効：3319　その他の血液代用剤 
 
一般名：酢酸維持液（ブドウ糖加） 

英名：Veen-3G
  
剤形：注射液

メーカー：興和

効能・効果：経口摂取不能又は不十分の水分・電解質の補給・維持、エネルギー補給

使用制限等
1. アジソン病、高カリウム血症、高窒素血症、重症熱傷、乏尿、高リン血症、低カルシウム血症、副甲状腺機能低下症、甲状腺機能低下症、高マグネシウム血症
2. 高カリウム血症を伴わない腎不全、心不全、閉塞性尿路疾患により尿量が減少、糖尿病

副作用等
1. 脳浮腫、肺水腫、末梢浮腫、水中毒、高カリウム血症
2. 酸塩基平衡異常、電解質異常

Clinical Experience with NIK-716 (Veen 3G Inj.) in Pediatrics.
Accession number：02A0492432 

Title：Clinical Experience with NIK-716 (Veen 3G Inj.) in Pediatrics.

Author：MATSUNO KATSUNORI (Kurume Univ., Fac. of Med.) HIKITA SHIGEKI (Kurume Univ., Fac. of Med.) MIZOTE HIROYOSHI (Kurume Univ., Fac. of Med.) 

Journal Title：Japanese Pharmacology & Therapeutics
 
Journal Code：Z0947A
 
ISSN：0386-3603
 
VOL.30;NO.4;PAGE.319-325(2002) 

Figure&Table&Reference：FIG.2, TBL.4, REF.20

Pub. Country：Japan

Language：Japanese

Abstract：The maintenance fluid Veen 3G Inj., acetated electrolyte solution containing 5% glucose, was administered to postoperative pediatric patients who were judged to be completely or partially unable to take a maintenance fluid by the oral or enteral route and require intravenous replacement of water, electrolytes and energy. Veen 3G Inj. was administered by intravenous infusion for up to 24 hours from postoperative day 1 (POD 1). Blood chemistry examination and urinalysis were performed before and after administration to assess the following three variables: 1) the replacement and maintenance of water (assessment of hydration and urine output) ; 2) the maintenance of serum electrolytes (Na and K) ; and 3 the utilization of glucose (blood glucose and urinary glucose). Having these variables within normal range was regarded as the indicator of efficacy of a maintenance fluid. Veen 3G Inj. proved effective in maintaining these variables within normal in all (100%) of the 25 pediatric patients who were evaluable for efficacy. As for its safety, Veen 3G Inj. produced no adverse events or abnormal laboratory values attributable to its infusion in any of the 29 children who received it and was thus judged to have posed no safety problem. The results obtained in this study where Veen 3G Inj. was administered to postoperative pediatric patients suggest that Veen 3G Inj. is a clinically useful and highly safe maintenance fluid. (author abst.)

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（20126700480021.PDF）的“原文Priscribing Information”为准
---------------------------------------------------------------